Eli Lilly's Weight-Loss Breakthrough: Zepbound Crushes Rivals, Stock Soars Nearly 44% YTD
Groundbreaking results show Zepbound outperforms Wegovy, revolutionizing obesity treatment and fueling massive investor gains ...
Eli Lilly says Zepbound’s weight-loss results beat those of rival Wegovy
Eli Lilly & Co. Inc.’s stock LLY rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective ...
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Key Takeaways Patients taking Eli Lilly's Zepbound lost more weight on average than those on Novo Nordisk's Wegovy in a new ...
Eli Lilly says 'Zepbound superior to Wegovy in head-to-head trial
Eli Lilly said Wednesday that its weight-loss medication Zepbound (tirzepatide) demonstrated superior efficacy over Novo ...
Eli Lilly's Zepbound Vs. Novo Nordisk's Wegovy - Which Shows Greater Weight Loss?
Eli Lilly's Zepbound outperformed Wegovy in weight loss and key outcomes during the SURMOUNT-5 trial, showing a comparable ...
Zepbound tops Wegovy for weight loss in Eli Lilly study
Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug ...
Eli Lilly says Zepbound beat rival weight loss drug Wegovy in head-to-head study
Zepbound is the “superior” choice for people looking to shed a few pounds, at least compared to Novo Nordisk’s (NVO) Wegovy, ...
Viking’s VK2735 likely ‘even better’ than Lilly’s Zepbound, says BTIG
After Eli Lilly (LLY) reported topline data from the Phase 3b SURMOUNT-5 trial, which ran a head-to-head comparison between Zepbound, or ...
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical ...
Lilly Says Zepbound Provided 47% Higher Relative Weight Loss Compared To Wegovy In SURMOUNT-5 Study
The study was designed to evaluate Zepbound compared with Novo Nordisk's Wegovy in adults with obesity with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep ...
Eli Lilly’s Zepbound outperforms Novo's Wegovy for weight loss in head-to-head trial
Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial, leading to a rise ...
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...